Fulgent Genetics (FLGT) AI Stock Analysis

• Market Cap: $682.89M
• Dividend Yield: N/A
• Average Volume (3M): 207.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: 4.31%
• EPS Growth: 69.57%
• Country: US
• Employees: 1,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.14
• Shares Outstanding: 30,609,043
• 10 Day Avg. Volume: 218,902
• 30 Day Avg. Volume: 207,342
• PEG Ratio: 0.17
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 1.97
• P/FCF Ratio: -29.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $28.00 ▲(21.16% Upside)

Fulgent Genetics' overall stock score reflects a mixed outlook. The positive momentum and strong earnings call guidance are significant strengths, suggesting potential growth. However, financial performance challenges and valuation concerns weigh down the score.

Fulgent Genetics Business Overview & Revenue Model

Company Description

Fulgent Genetics (FLGT) is a leading genomic testing company that specializes in providing comprehensive genetic testing services. The company operates primarily in the healthcare sector, focusing on advanced molecular diagnostics, including genetic testing for various conditions such as inherited diseases, infectious diseases, and oncology. Fulgent offers a wide range of services, including next-generation sequencing (NGS) and custom testing solutions, catering to both healthcare providers and patients, with a mission to improve patient outcomes through precision medicine.

How the Company Makes Money

Fulgent Genetics generates revenue primarily through its genetic testing services. The company's revenue model is based on the fees charged for its diagnostic tests, which include both routine and custom genomic tests. Key revenue streams include individual tests for hereditary cancer, infectious diseases, and other genetic conditions, as well as partnerships with healthcare institutions and laboratories that utilize Fulgent's testing capabilities. Additionally, Fulgent has established collaborations with pharmaceutical companies and research institutions, which contribute to its earnings by providing specialized testing services and insights for clinical trials and drug development. The company's ability to innovate and adapt its testing offerings to meet the evolving needs of the healthcare market also plays a significant role in sustaining its revenue growth.

Fulgent Genetics Financial Statement Overview

Summary

Fulgent Genetics is facing financial difficulties with declining revenues and profitability since 2021. The balance sheet remains strong with low leverage, but cash flow issues are concerning. The company needs to address operational inefficiencies and improve cash generation to stabilize its financial position.

Income Statement

Fulgent Genetics has experienced a significant decline in revenue and profitability over the past few years. The TTM data shows a slight revenue growth of 4.07%, but the company is still operating at a loss with a net profit margin of -13.62%. Historical data reveals a sharp decline from 2021, when the company had a net profit margin of 51.12%. The EBIT and EBITDA margins have also deteriorated, indicating operational challenges.

Balance Sheet

The balance sheet remains relatively strong with a very low debt-to-equity ratio of 0.0004 in the TTM period, indicating minimal leverage. However, the return on equity is negative at -3.82%, reflecting the company's current unprofitability. The equity ratio is stable, suggesting a solid capital structure despite recent losses.

Cash Flow

Cash flow metrics indicate challenges, with a significant decline in free cash flow growth and a negative free cash flow to net income ratio of -13.03 in the TTM period. The operating cash flow to net income ratio is low at 0.021, highlighting cash generation issues. Historical data shows a drastic reduction in free cash flow from 2021 levels.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	315.55M	283.47M	289.21M	618.97M	992.58M	421.71M
Gross Profit	130.14M	107.22M	104.46M	366.90M	777.05M	331.90M
EBITDA	-38.01M	-48.99M	-147.45M	217.70M	686.96M	293.12M
Net Income	-42.98M	-42.71M	-167.82M	143.40M	507.36M	214.31M
Balance Sheet
Total Assets	1.21B	1.22B	1.24B	1.39B	1.28B	700.46M
Cash, Cash Equivalents and Short-Term Investments	375.80M	258.11M	424.15M	526.24M	450.50M	299.37M
Total Debt	476.00K	8.47M	15.25M	38.94M	21.28M	15.85M
Total Liabilities	93.81M	90.81M	102.04M	116.18M	112.84M	131.07M
Stockholders Equity	1.13B	1.13B	1.14B	1.27B	1.16B	569.39M
Cash Flow
Free Cash Flow	-19.85M	-19.25M	4.80M	234.75M	514.73M	104.12M
Operating Cash Flow	1.52M	21.06M	27.00M	253.52M	538.58M	140.63M
Investing Cash Flow	72.76M	-58.35M	38.90M	-261.31M	-546.55M	-326.44M
Financing Cash Flow	-14.58M	-4.85M	-47.78M	-77.14M	85.39M	261.25M

Fulgent Genetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLGT, the sentiment is Positive. The current price of 23.11 is below the 20-day moving average (MA) of 23.19, above the 50-day MA of 22.68, and above the 200-day MA of 19.72, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 72.22 is Negative, neither overbought nor oversold. The STOCH value of 45.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLGT.

Fulgent Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	64 Neutral	$803.38M	13.10	24.11%	―	14.46%	―
CSTL	62 Neutral	$979.28M	―	-2.69%	―	10.15%	-295.52%
FLGT	60 Neutral	$682.89M	―	-4.54%	―	4.31%	69.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	51 Neutral	$587.25M	―	-72.52%	―	0.21%	-233.51%
PSNL	43 Neutral	$638.06M	―	-43.69%	―	-21.02%	47.74%
LAB	41 Neutral	$454.57M	-3.72	-24.63%	―	-17.37%	52.28%

Fulgent Genetics Corporate Events

Fulgent Genetics Reports Strong Q3 2025 Growth

Fulgent Genetics, Inc. is a technology-driven company operating in the laboratory services and therapeutic development sectors, focusing on cancer treatment innovations through its nanoencapsulation and targeted therapy platform.

Fulgent Genetics Raises 2025 Revenue Guidance

Fulgent Genetics reported its third quarter 2025 financial results, showing a revenue of $84.1 million, a 17% increase year-over-year, and a GAAP loss of $6.6 million. The company raised its full-year 2025 revenue guidance to $325.0 million and expects to end the year with approximately $800.0 million in cash and investments, demonstrating strong momentum in its laboratory services and therapeutic development businesses.

The most recent analyst rating on (FLGT) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.

Fulgent Genetics Presents Promising Phase 2 Trial Data

On October 20, 2025, Fulgent Genetics announced preliminary clinical data from its ongoing phase 2 trial of FID-007 in combination with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO 2025 Conference, showed promising anticancer efficacy and a favorable safety profile, suggesting potential advancements in oncology treatments. This development supports Fulgent’s mission to provide comprehensive cancer care solutions, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (FLGT) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.